

**IPAR**



**Publicly Available Assessment Report for a  
Veterinary Medicinal Product**

---

Bimprocil 300mg/ml suspension for injection for cattle, sheep and pigs

**PRODUCT SUMMARY**

EU Procedure number	IE/V/0649/001/DC
Name, strength and pharmaceutical form	Bimprocil 300 mg/ml suspension for injection for cattle sheep and pigs
Active substance(s)	Benzylpenicillin procaine
Applicant	Bimeda Animal Health Limited 2, 3 & 4 Airton Close Airton Road Tallaght Dublin 24 Ireland
Legal basis of application	Generic application in accordance with Article 13.1 of Directive 2001/82/EC as amended.
Date of completion of procedure	3 <sup>rd</sup> March 2021
Target species	Cattle, sheep and pigs.
Indication for use	For the treatment of acute systemic infections caused by bacteria susceptible to benzylpenicillin.
ATC vet code	QJ01CE09
Concerned Member States	AT, BE, DE, ES, FR, NL, IT, PL, PT, UK(NI)

**PUBLIC ASSESSMENT REPORT**

The public assessment report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

**I. SCIENTIFIC OVERVIEW**

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.  
The overall benefit/risk analysis is in favour of granting a marketing authorisation.

**II. QUALITY ASPECTS****A. Qualitative and Quantitative Particulars**

The product contains 300 mg/ml of benzylpenicillin procaine and the excipients disodium edetate, lecithin, methylparahydroxybenzoate, povidone, sodium citrate, potassium dihydrogen phosphate, potassium chloride and water for injections.

The container/closure system is 100 ml clear, Type I glass and 250 ml clear, Type III glass, multidose vials, with bromobutyl rubber stoppers and aluminium overseals.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

#### **B. Method of Preparation of the Product**

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data for the manufacturing process has been presented in accordance with the relevant European guidelines.

#### **C. Control of Starting Materials**

The active substance is benzylpenicillin procaine, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification has been provided.

#### *Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies*

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

#### **D. Control on Intermediate Products**

Not applicable.

#### **E. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods has been provided.

Batch analytical data from the proposed production site has been provided demonstrating compliance with the specification.

#### **F. Stability**

Stability data on the active substances has been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions

Stability data on the finished product has been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

#### **G. Other Information**

Not applicable.

### **III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)**

The Application was made in accordance with Article 13(1) of Directive 2001/82/EC, as amended (a generic application). The reference product cited by the Applicant is Procillin Injection, 300 mg/ml suspension for injection marketed by the same marketing authorisation holder (Bimeda Animal Health Limited).

Bioequivalence is granted according to waiver 7.1.d of the Guideline (EMA/CVMP/016/2000-Rev.3) which states:

'The formulations are identical (identical active substances and excipients as well as physicochemical properties [e.g. identical concentration, dissolution profile, crystalline form, pharmaceutical form and particular size distribution with identical manufacturing process]).'

### **III. SAFETY ASSESSMENT**

#### **III.A Safety Testing**

##### **Pharmacological Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of other pharmacological tests are not required.

**Toxicological Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of other toxicological tests are not required.

**User Safety**

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that paraben preservative and penicillin may cause allergic reactions following injection, ingestion or skin contact. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

**Environmental Risk Assessment****Phase I**

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the Predicted Environmental Concentration (PEC) for soil for cattle, sheep and pigs was below the trigger value of 100 µg/kg.

**Conclusion**

Based on the data provided, the ERA can stop at Phase I. The product is not expected to pose an unacceptable risk for the environment when used according to the SPC.

**III.B Residues Documentation****Residue Studies**

No residue depletion studies were conducted due to the identical qualitative and quantitative compositions of the generic and reference product.

**MRLs**

Benzylpenicillin procaine is listed in Table I of the Annex to Commission Regulation (EU) No 37/2010 as follows:

	<b>Cattle, Sheep &amp; Pigs</b>
Muscle	50 µg/kg
Liver	50 µg/kg
Kidney	50 µg/kg
Fat / skin	50 µg/kg
Milk	4 µg/kg

**Withdrawal Periods**

Based on the data provided above, and taking account of the Article 82 referral for veterinary medicinal products containing procaine benzylpenicillin, withdrawal periods of 10 days (treatment duration of 3 days) and 12 days (treatment duration 4-7 days) for meat and offal in cattle; 7 days (treatment duration 3 days) and 9 days (treatment duration 4-7 days) for meat and offal in pigs; 4 days (treatment duration 3 days) and 6 days (treatment duration 4-7 days) for meat and offal in sheep, and 108 hours for milk in cattle were approved. The product is not authorised for use in sheep producing milk for human consumption.

**IV. CLINICAL ASSESSMENT**

As this is a generic application according to Article 13(1) of Directive 2001/82/EC as amended, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

**IV.A Pre-Clinical Studies****Tolerance in the Target Species of Animals**

As this is a generic application according to Article 13, bioequivalence with a reference product has been demonstrated, and the product is intended to be administered to the same target species, using the same route of administration at the same dose rate as already approved for the reference product, results of animal tolerance safety are not required.

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

### **Resistance**

Adequate warnings and precautions appear on the product literature.

## **V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

## **VI. POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

### **Changes:**

Summary of change (Application number)	Approval date
C.2 VNRA: Introduction of changes to the SPC arising from the outcome of the Article 82 referral for veterinary medicinal products containing procaine benzylpenicillin as a single active substance presented as suspensions for injection EMA/V/A/145 .	August 2024